The most dangerous side effect of allogeneic blood stem cell transplantation, graft-versus-host disease (GvHD), has still not been sufficiently researched. The world’s largest blood stem cell donor center DKMS wants to change that – it is the declared goal of the non-profit organization to improve the survival and healing chances of blood cancer patients. In the fight against GvHD, DKMS research teams have now launched two new scientific studies.